Healthequity (HQY) Stock Value Rose While Fcm Investments Lowered Its Holding; Baker Bros Advisors LP Increased Seattle Genetics (SGEN) Stake by $510,000

November 14, 2017 - By Clifton Ray

Julian Baker increased its stake in Seattle Genetics Inc. (SGEN) by 0.02% based on its latest 2017Q2 regulatory filing with the SEC. Baker Bros Advisors Lp bought 10,000 shares as the company’s stock rose 1.68% with the market. The hedge fund run by Julian Baker held 45.73M shares of the health care company at the end of 2017Q2, valued at $2.37 billion, up from 45.72M at the end of the previous reported quarter. Baker Bros Advisors Lp who had been investing in Seattle Genetics Inc. for a number of months, seems to be bullish on the $8.18 billion market cap company. The stock declined 0.56% or $0.32 reaching $56.8 on the news. About 19,729 shares traded. Seattle Genetics, Inc. (NASDAQ:SGEN) has risen 75.68% since November 14, 2016 and is uptrending. It has outperformed by 58.98% the S&P500.

Fcm Investments decreased its stake in Healthequity Inc. (HQY) by 16.86% based on its latest 2017Q2 regulatory filing with the SEC. Fcm Investments sold 15,251 shares as the company’s stock rose 4.44% with the market. The hedge fund held 75,200 shares of the miscellaneous company at the end of 2017Q2, valued at $3.75M, down from 90,451 at the end of the previous reported quarter. Fcm Investments who had been investing in Healthequity Inc. for a number of months, seems to be less bullish one the $2.97 billion market cap company. The stock declined 1.76% or $0.88 reaching $49.17 per share. About 30,737 shares traded. Healthequity Inc (NASDAQ:HQY) has risen 95.58% since November 14, 2016 and is uptrending. It has outperformed by 78.88% the S&P500.

Among 18 analysts covering Seattle Genetics (NASDAQ:SGEN), 7 have Buy rating, 0 Sell and 11 Hold. Therefore 39% are positive. Seattle Genetics had 56 analyst reports since July 31, 2015 according to SRatingsIntel. Guggenheim initiated Seattle Genetics, Inc. (NASDAQ:SGEN) rating on Monday, October 23. Guggenheim has “Buy” rating and $72.0 target. RBC Capital Markets maintained it with “Outperform” rating and $54 target in Monday, September 14 report. The firm has “Hold” rating by Cantor Fitzgerald given on Monday, June 19. The firm earned “Buy” rating on Tuesday, August 25 by William Blair. As per Wednesday, July 27, the company rating was downgraded by Cantor Fitzgerald. JP Morgan maintained the stock with “Neutral” rating in Monday, October 30 report. The stock of Seattle Genetics, Inc. (NASDAQ:SGEN) has “Outperform” rating given on Thursday, January 21 by Credit Suisse. The firm has “Hold” rating by Cowen & Co given on Monday, June 26. The firm has “Hold” rating given on Tuesday, August 29 by Cantor Fitzgerald. Barclays Capital downgraded the stock to “Equal-Weight” rating in Tuesday, November 29 report.

Baker Bros Advisors Lp, which manages about $8.20 billion and $11.44 billion US Long portfolio, decreased its stake in Sangamo Therapeutics Inc. (NASDAQ:SGMO) by 417,525 shares to 4.11 million shares, valued at $36.20 million in 2017Q2, according to the filing. It also reduced its holding in Neurocrine Biosciences Inc. (NASDAQ:NBIX) by 278,740 shares in the quarter, leaving it with 616,682 shares, and cut its stake in Bluebird Bio Inc. (NASDAQ:BLUE).

Investors sentiment decreased to 1.3 in 2017 Q2. Its down 0.20, from 1.5 in 2017Q1. It is negative, as 30 investors sold SGEN shares while 75 reduced holdings. 48 funds opened positions while 89 raised stakes. 137.48 million shares or 0.82% less from 138.62 million shares in 2017Q1 were reported. Quantbot Technologies Limited Partnership owns 0.01% invested in Seattle Genetics, Inc. (NASDAQ:SGEN) for 1,226 shares. Tradewinds Capital Mngmt Limited Liability has invested 0.06% in Seattle Genetics, Inc. (NASDAQ:SGEN). Peak6 Invs Lp holds 6,518 shares or 0% of its portfolio. Bancshares Of America De holds 0% in Seattle Genetics, Inc. (NASDAQ:SGEN) or 406,493 shares. Guardian Tru Co owns 584,256 shares. Baker Bros Advsr Lp stated it has 45.73 million shares. Tiaa Cref Mgmt reported 753,152 shares. Jpmorgan Chase & holds 0% of its portfolio in Seattle Genetics, Inc. (NASDAQ:SGEN) for 3,562 shares. Ubs Asset Americas stated it has 375,642 shares or 0% of all its holdings. First Advisors Lp holds 0.13% of its portfolio in Seattle Genetics, Inc. (NASDAQ:SGEN) for 937,383 shares. Sei Investments Co invested in 0% or 5,732 shares. Verition Fund Mngmt Lc has 0.03% invested in Seattle Genetics, Inc. (NASDAQ:SGEN) for 6,524 shares. Great West Life Assurance Can invested in 43,539 shares. Pdts Prtn Ltd Liability Com stated it has 166,246 shares or 0.35% of all its holdings. Eagle Asset Management Inc has 299,804 shares for 0.09% of their portfolio.

Since May 31, 2017, it had 0 insider purchases, and 2 selling transactions for $1.31 million activity. HIMES VAUGHN B had sold 10,000 shares worth $625,922 on Wednesday, May 31.

More notable recent Seattle Genetics, Inc. (NASDAQ:SGEN) news were published by: Barrons.com which released: “Seattle Genetics May See ‘Significant Upside'” on October 25, 2017, also Seekingalpha.com with their article: “Your Daily Pharma Scoop: Timing Synergy Trade, Valeant’s Vyzulta Approved …” published on November 03, 2017, Fool.com published: “Seattle Genetics results: The raw numbers” on November 01, 2017. More interesting news about Seattle Genetics, Inc. (NASDAQ:SGEN) were released by: Businesswire.com and their article: “(Brentuximab Vedotin) for Primary Cutaneous Anaplastic Large Cell Lymphoma …” published on November 09, 2017 as well as Bna.com‘s news article titled: “Seattle Genetics Defeats Class Stock Fraud Suit Over Cancer Drug” with publication date: October 20, 2017.

Another recent and important Healthequity Inc (NASDAQ:HQY) news was published by Globenewswire.com which published an article titled: “HealthEquity’s Ashley Dreier Honored By The Women Tech Council For Technology …” on November 01, 2017.

Fcm Investments, which manages about $373.26M and $130.87 million US Long portfolio, upped its stake in Copart (NASDAQ:CPRT) by 16,605 shares to 107,092 shares, valued at $3.40 million in 2017Q2, according to the filing.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Twitter Auto Publish Powered By : XYZScripts.com